Literature DB >> 19364452

Corticobasal degeneration.

Stephen G Reich1, Stephen E Grill.   

Abstract

Corticobasal degeneration (CBD) is a neurodegenerative disorder characterized clinically by a combination of cortical and basal ganglia signs. Pathologically, it is classified as a tauopathy. The most distinctive clinical feature is its unilateral or markedly asymmetric presentation; among parkinsonian syndromes, with rare exceptions, only Parkinson's disease presents with such asymmetry. The most common presenting cortical features include apraxia (patients often complain of a "useless" limb), aphasia (usually nonfluent), parietal lobe sensory signs (agraphesthesia, extinction, astereognosis), frontal dementia, or myoclonus. Basal ganglia signs include rigidity, akinesia, limb dystonia, and postural instability. The diagnosis is often challenging for three reasons: 1) The full complement of findings are rarely seen at presentation; 2) If CBD is not suspected, subtle but relevant findings (eg, extinction, language impairment, myoclonus, or apraxia) may not be searched for or appreciated; 3) The clinical picture of CBD has substantial overlap with a variety of other parkinsonian and dementing illnesses. The differential diagnosis includes Parkinson's disease, progressive supranuclear palsy, frontotemporal dementia, primary progressive aphasia, and Alzheimer's disease. The clinical diagnosis is not confirmed pathologically in up to half of cases, so the term corticobasal syndrome is often preferred during life, reserving the term corticobasal degeneration for pathologically verified cases. Treatment of CBD is primarily supportive, and most patients die within 10 years of onset. Parkinsonian signs may improve to a modest degree with levodopa, clonazepam can suppress myoclonus, and botulinum toxin can relieve dystonia. Early speech therapy, physical therapy, and occupational therapy, as well as assist devices such as a rolling walker may improve functioning and reduce complications such as aspiration pneumonia and falls. With time, however, most patients lose their independence and mobility. Throughout the course of the illness (particularly when it is advanced), caring for the caregiver is as important as caring for the patient.

Entities:  

Year:  2009        PMID: 19364452     DOI: 10.1007/s11940-009-0021-9

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  34 in total

1.  Abnormalities of optokinetic nystagmus in progressive supranuclear palsy.

Authors:  S Garbutt; D E Riley; A N Kumar; Y Han; M R Harwood; R J Leigh
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-10       Impact factor: 10.154

2.  Cortical-basal ganglionic degeneration.

Authors:  D E Riley; A E Lang; A Lewis; L Resch; P Ashby; O Hornykiewicz; S Black
Journal:  Neurology       Date:  1990-08       Impact factor: 9.910

Review 3.  Recent advances in the understanding of tau protein and movement disorders.

Authors:  Z Arvanitakis; Z K Wszolek
Journal:  Curr Opin Neurol       Date:  2001-08       Impact factor: 5.710

4.  Treatment of dystonic clenched fist with botulinum toxin.

Authors:  C Cordivari; V P Misra; S Catania; A J Lees
Journal:  Mov Disord       Date:  2001-09       Impact factor: 10.338

5.  Brain perfusion SPECT in patients with corticobasal degeneration: analysis using statistical parametric mapping.

Authors:  A K M Moinul Hossain; Yuji Murata; Lin Zhang; Shin-ichi Taura; Yukinobu Saitoh; Hidehiro Mizusawa; Kenji Oda; Eisuke Matsushima; Yoshiro Okubo; Hitoshi Shibuya
Journal:  Mov Disord       Date:  2003-06       Impact factor: 10.338

6.  The alien hand and related signs.

Authors:  R S Doody; J Jankovic
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-09       Impact factor: 10.154

7.  Corticodentatonigral degeneration with neuronal achromasia.

Authors:  J J Rebeiz; E H Kolodny; E P Richardson
Journal:  Arch Neurol       Date:  1968-01

Review 8.  Levodopa responsiveness in disorders with parkinsonism: a review of the literature.

Authors:  Radu Constantinescu; Irene Richard; Roger Kurlan
Journal:  Mov Disord       Date:  2007-11-15       Impact factor: 10.338

9.  Imaging of corticobasal degeneration syndrome.

Authors:  Masamichi Koyama; Akira Yagishita; Yasuhiro Nakata; Masaharu Hayashi; Mitsuaki Bandoh; Toshio Mizutani
Journal:  Neuroradiology       Date:  2007-07-14       Impact factor: 2.804

10.  Clinical presentation and pharmacological therapy in corticobasal degeneration.

Authors:  K Kompoliti; C G Goetz; B F Boeve; D M Maraganore; J E Ahlskog; C D Marsden; K P Bhatia; P E Greene; S Przedborski; E C Seal; R S Burns; R A Hauser; L L Gauger; S A Factor; E S Molho; D E Riley
Journal:  Arch Neurol       Date:  1998-07
View more
  6 in total

1.  Apathy in corticobasal degeneration: possible parietal involvement.

Authors:  Rita Moretti; R Caberlotto; R Signori
Journal:  Funct Neurol       Date:  2017 Oct/Dec

2.  Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options.

Authors:  Gregory A Jicha; Peter T Nelson
Journal:  Neurodegener Dis Manag       Date:  2011-04

3.  Progressive Supranuclear Palsy and Corticobasal Degeneration.

Authors:  David G Coughlin; Dennis W Dickson; Keith A Josephs; Irene Litvan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  The genetics of dystonias.

Authors:  Mark S LeDoux
Journal:  Adv Genet       Date:  2012       Impact factor: 1.944

5.  Metabolite and lipoprotein profiles reveal sex-related oxidative stress imbalance in de novo drug-naive Parkinson's disease patients.

Authors:  Gaia Meoni; Leonardo Tenori; Sebastian Schade; Cristina Licari; Chiara Pirazzini; Maria Giulia Bacalini; Paolo Garagnani; Paola Turano; Claudia Trenkwalder; Claudio Franceschi; Brit Mollenhauer; Claudio Luchinat
Journal:  NPJ Parkinsons Dis       Date:  2022-02-08

6.  Early and severe cognitive impairment in multiple sclerosis.

Authors:  Maria Fernanda Mendes; Alessandro Finkelsztejn; Sidney Gomes; Yára Dadalti Fragoso
Journal:  Dement Neuropsychol       Date:  2012 Jan-Mar
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.